BTIG Research and Strategy Bolsters Life Science and Diagnostic Tools Coverage with Senior Analyst Mark Massaro

NEW YORK–(BUSINESS WIRE)–BTIG announced today that Mark Massaro has joined the firm’s Healthcare Research team as a Managing Director and Life Science and Diagnostic Tools Analyst. Mr. Massaro will be based in BTIG’s Boston office and report to David Lenchus, Director of Research, at BTIG.

Prior to BTIG, Mr. Massaro served as the Chief Financial Officer at ArcherDX, Inc., an oncology diagnostics and pharmaceutical services company. Previously, he was a Managing Director and Senior Equity Research Analyst within Diagnostics and Life Science Tools at Canaccord Genuity, where he spent more than eight years focused on high-growth, precision medicine and next-generation sequencing companies, as well as molecular and point-of-care diagnostics, reference labs and animal health. Mr. Massaro was named a “Rising Star” in Institutional Investor’s All America Survey for life science and diagnostics tools in October 2016. Earlier in his career, he was an Associate Equity Analyst within Healthcare Services at Avondale Partners and held corporate finance and financial reporting roles at Dell EMC and Fidelity Investments. Mr. Massaro earned an MBA from Babson College and a BA in economics and Spanish from the University of Massachusetts – Amherst.

“We are thrilled to add Mark to the Research and Strategy team,” said Mr. Lenchus. “Given his corporate leadership experience and over a decade as a sell-side life science and diagnostic tools analyst, we believe he will bring an important perspective to clients as they evaluate their investments and the healthcare marketplace.”

With Mr. Massaro, BTIG will now have two research analysts exclusively focused on the life science and diagnostic tools vertical at the firm, where Sung Ji Nam has covered the space since 2017. Other BTIG publishing healthcare analysts include Biotechnology Analysts Bert Hazlett, Thomas Shrader, PhD, CFA, Dae Gon Ha, PhD, and Julian Harrison, Medical Technology and Digital Health Analyst Marie Thibault, and Medical Technology Analyst Ryan Zimmerman.

BTIG Research and Strategy provides comprehensive reports, industry observations and other insights for clients. The team’s sector focus includes consumer, energy, financials, healthcare, real estate, shipping, and technology, media and telecommunications. Visit www.btigresearch.com to learn more.

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 600 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit www.btig.com.

Contacts

Jill Gordon
646.818.9226

jgordon@prosek.com

Amanda Gold
212.738.6134

agold@btig.com

Staff

Recent Posts

Global Microscopy Market to Reach USD 10.6 Billion by 2029 driven by Healthcare Innovations | MarketsandMarkets™

CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…

2 hours ago

FSD Pharma Files Amended and Restated Material Change Report

Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…

5 hours ago

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…

5 hours ago

ICPO Foundation partners with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center

ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…

5 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

5 hours ago